Following the third meeting of the Aker BioMarine Science Board (ASB) in Alesund, Norwary, Aker BioMarine, in council with leading neuroscientists, will fund a study on the neuroproductive health effects of krill oil.
ASB memberts, including (identify two of the board members who will be quoted in the press release), were joined by outside experts in neuroscience.
Adina Michael-Titus, Professor of Nueroscience at the Center for Neuroscience and Trauma in London, England spoke about the potential effects of unsaturated fatty acids on post-traumatic brain injuries. Professor Kristinn Johnsen of Iceland spoke about Metiscura and non-invasive EEG techniques. Professor Alex Richardson spoke about the paliative effects of krill oil and its effects on anxiety in adults. And Professor Paul Montgomery of the University of Oxford, England, spoke about the impact of polyunsaturated fats on sleep and resulting changes in mental status.
“Based on the intensive discussions with our four guest lecturers, the Board has determined that a clinical study of the effects of krill oil on XXXX is necessary and timely. The outcome of this research can have a significant and immediate impact (for people suffering from…),” says XXXX of the ASB.
Aker BioMarine is the only krill ingredient marketer that is primary in its supply. Aker’s proprietary Eco-Harvesting™ technology and on-board processing result in the unique composition of Superba™ Krill Oil and provide full traceability from sea to shelf. The Marine Stewardship Council (MSC) has granted MSC Certification to Aker’s fisheries, an exclusive distinction that no other krill fishery has earned. As part of an established commitment to substantiating krill’s health benefits, Aker continues to sponsor in vitro, in vivo, and human clinical trials with phospholipid EPA & DHA from krill oil, consistently demonstrating a higher uptake of phospholipid omega-3 fatty acids, improved blood lipid profiles, and increased uptake of DHA in brain tissue compared to other omega-3 fatty acid sources.